Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2015 Jun;32(2):180-3.
doi: 10.4274/tjh.2013.0338.

Ruxolitinib Treatment in a Patient with Primary Myelofibrosis Resistant to Conventional Therapies and Splenectomy: A Case Report

Meltem Aylı, Muhit Özcan, Güldane Cengiz Seval  1
Affiliations
Case Reports

Ruxolitinib Treatment in a Patient with Primary Myelofibrosis Resistant to Conventional Therapies and Splenectomy: A Case Report

Meltem Aylı et al. Turk J Haematol. 2015 Jun.

Abstract
in English, Turkish

A 67-year-old male patient who was diagnosed with primary myelofibrosis 4 years ago did not respond to conventional therapies. The splenomegaly progressively increased, which caused spleen infarctions and led to the decision to perform a splenectomy procedure. After splenectomy, the patient started treatment with ruxolitinib. In the first month of ruxolitinib treatment, the patient became transfusion-free and all constitutional symptoms disappeared. However, in the sixth month of ruxolitinib treatment, the disease transformed to acute myeloblastic leukemia, and the patient died 1 month later. This is the first case report that shows the effects of ruxolitinib in a splenectomized patient.

Dört yıl önce primer myelofibrozis tanısı konulan 67 yaşındaki erkek hastaya uygulanan konvansiyonel tedavi yöntemleri ile sonuç alınamadı. Dalak boyutları ileri derecede arttı, hastanın tekrar ayda 4-6 ünite transfüzyon gereksinimi olmaya başladı. Bu dönemde dev boyutlara ulaşan dalakta infarktüs gelişti ve hastaya splenektomi yaptırıldı. Splenektomi sonrası hastaya ruxolitinib başlandı. Ruxolitinib tedavisinin 1. ayından itibaren hasta transfüzyon bağımsız hale geldi, tüm konstitüsyonel semptomlar ortadan kalktı. Ancak ruxolitinib tedavisinin 6. ayında hasta akut myeloblastik lösemiye (AML) transfore oldu. Ve AML tedavisinin 1. ayında hasta kaybedildi. Bu olgu splenektomi yapılmış bir hastada ruxolitinib etkisini gösteren ilk olgudur.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Statement

The author of this paper has no conflicts of interest, including specific financial interests, relationships, and/or affiliations relevant to the subject matter or materials included.

References

    1. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med. 2000;342:1255–1265. - PubMed
    1. Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer. 2007;7:673–683. - PubMed
    1. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779–1790. - PubMed
    1. Vaddi K, Sarlis NJ, Gupta V. Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis. Expert Opin Pharmacother. 2012;13:2397–2407. - PubMed
    1. Abdel-Wahab OI, Levine RL. Primary myelofibrosis: update on definition, pathogenesis, and treatment. Annu Rev Med. 2009;60:233–245. - PubMed

Publication types

MeSH terms

LinkOut - more resources